Selamectin

Names

[ CAS No. ]:
220119-17-5

[ Name ]:
Selamectin

[Synonym ]:
(2aE,4E,5'S,6S,6'S,7S,8E,11R,13R,15S,17aR,20Z,20aR,20bS)-6'-cyclohexyl-20b-hydroxy-20-(hydroxyimino)-5',6,8,19-tetramethyl-17-oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-tetradecahydro-2H,7H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacyclooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-3-O-methyl-α-L-arabino-hexopyranoside
(1'R,2R,4'S,5S,6S,8'R,10'E,12'S,13'S,14'E,16'E,20'R,21'Z,24'S)-6-Cyclohexyl-24'-hydroxy-21'-(hydroxyimino)-5,11',13',22'-tetramethyl-2'-oxo-3,4,5,6-tetrahydrospiro[pyran-2,6'-[3,7,19]trioxatetracyclo[ ;15.6.1.1.0]pentacosa[10,14,16,22]tetraen]-12'-yl 2,6-dideoxy-3-O-methyl-α-L-arabino-hexopyranoside
hypnocarpic acid
(1'R,2R,4'S,5S,6S,8'R,10'E,12'S,13'S,14'E,16'E,20'R,21'Z,24'S)-6-Cyclohexyl-24'-hydroxy-21'-(hydroxyimino)-5,11',13',22'-tetramethyl-2'-oxo-3,4,5,6-tetrahydrospiro[pyran-2,6'-[3,7,19]trioxatetracyclo[15.6.1.1.0]pentacosa[10,14,16,22]tetraen]-12'-yl-2,6-dideoxy-3-O-methyl-α-L-arabino-hexopyranoside
(1'R,2R,4'S,5S,6S,8'R,10'E,12'S,13'S,14'E,16'E,20'R,21'Z,24'S)-6-Cyclohexyl-24'-hydroxy-21'-(hydroxyimino)-5,11',13',22'-tetramethyl-2'-oxo-3,4,5,6-tetrahydrospiro[pyran-2,6'-[3,7,19]trioxatetracyclo[15.6.1.1.0]pentacosa[10,14,16,22]tetraen]-12'-yl 2,6-dideoxy-3-O-methyl-α-L-arabino-hexopyranoside
Stronghold
Selamectin
Revolution

Biological Activity

[Description]:

Selamectin is an anthelminthic which can be used on dogs and cats.

[Related Catalog]:

Signaling Pathways >> Others >> Others

Research Areas >> Infection

[In Vivo]

Three monthly treatments with Selamectin/sarolaner provide high and consistent efficacy against I. ricinus for the entire duration of the study period. The percentage efficacy against I. ricinus is numerically higher in the Selemectin/sarolaner treating group than in the fluralaner-treating group on Days 56, 84 and 91[1]. All dogs are tested negative by both tests after receiving topical treatment with Selamectin monthly for 36 months[2].

[Animal admin]

The cats are weighed on Days-2, 29 and 58 to calculate the dosing. Cats in group 1 (control group) remain untreated. On Day 0, the cats in group 3 are treated with fluralaner at the minimum recommending label dose of 40.0 mg per kg body weight. On Days 0, 30 and 60, the cats in group 2 are treated with the new spot-on formulation at the minimum recommending label dose of 1.0 mg/kg sarolaner and 6.0 mg/kg Selamectin. The cats are observed at different time points after treatment for possible adverse reactions to treatment. On Day 0, administration site observations are performed on all cats 30 min (±5 min), 3 h (±15 min) and 24 h (±1 h) and again on Days 3 and 5 after treatment[1].

[References]

[1]. Thomas Geurden, et al. Comparative efficacy of a new spot-on combination product containing selamectin and sarolaner (Stronghold®Plus) versus fluralaner (Bravecto®) against induced infestations with Ixodes ricinus ticks on cats. Published online 2017 Jun 29.

[2]. Maria de Fátima Chicarino Varajao Moraes-da-Silva, et al. Selamectin for the prevention of canine Dirofilaria immitis infection: field efficacy in client-owned dogs in a high risk area. Published online 2016 Jul 22.

[Related Small Molecules]

Chemical & Physical Properties

[ Density]:
1.4±0.1 g/cm3

[ Boiling Point ]:
917.0±65.0 °C at 760 mmHg

[ Molecular Formula ]:
C₄₃H₆₃NO₁₁

[ Molecular Weight ]:
769.960

[ Flash Point ]:
508.4±34.3 °C

[ Exact Mass ]:
769.440125

[ PSA ]:
154.73000

[ LogP ]:
6.83

[ Vapour Pressure ]:
0.0±0.6 mmHg at 25°C

[ Index of Refraction ]:
1.618

[ Storage condition ]:
2-8°C

Safety Information

[ RIDADR ]:
NONH for all modes of transport

Articles

Determination of avermectins: a QuEChERS approach to the analysis of food samples.

Food Chem. 181 , 57-63, (2015)

We present a simple method for extracting avermectines from meat, based on a QuEChERS approach followed by liquid chromatography (LC) coupled to triple quadrupole (QqQ) tandem mass spectrometry (MS/MS...

The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer.

EMBO Mol. Med. 6(10) , 1263-78, (2014)

Constitutive activation of canonical WNT-TCF signaling is implicated in multiple diseases, including intestine and lung cancers, but there are no WNT-TCF antagonists in clinical use. We have performed...

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.